In:
Cancer, Wiley, Vol. 127, No. 19 ( 2021-10), p. 3614-3621
Abstract:
In this study, a reduction in human papillomavirus (HPV) prevalence from a prevaccine period to a postvaccine period was not observed, likely attributable to a low number of cases and low HPV‐vaccination coverage in the postvaccine period. However, using the framework for obtaining HPV‐genotyping information from population‐based cancer registries could be an important strategy for monitoring HPV prevalence and impact of the HPV vaccine, particularly in younger women who are more likely to have been vaccinated.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v127.19
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1